The second-line treatment for chemotherapy-resistant CRC liver metastases with acquired KRAS mutations and elevated AURKA/c-MYC expression is EGFR pathway blockade combined with AURKA inhibition using CRC-like organoids and metastatic CRC-like organoids [55]. Here, MYC is linked to colorectal carcinoma.